Aytu Biopharma, Inc SEC filings AYTU
Aytu Biopharma, Inc has 907 filings in SEC EDGAR's recent list, going back to Jan 11, 2007. Its latest annual report, Form 10-K, was filed on Sep 22, 2026 for the period ended Jun 30, 2026. The latest quarterly report (Form 10-Q) was filed on May 13, 2026, covering the quarter ended Mar 31, 2026. The most recent current report (Form 8-K) was filed on Sep 22, 2026 (results of operations). The company's fiscal year ends on June 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Oct 27, 2026 | — |
| DEF 14A | Proxy statement | Oct 22, 2026 | Dec 10, 2026 |
| DEFA14A | Additional proxy material | Oct 24, 2025 | — |
| DEF 14A | Proxy statement | Oct 24, 2025 | Dec 10, 2025 |
| DEFA14A | Additional proxy material | Mar 28, 2025 | — |
| DEF 14A | Proxy statement | Mar 28, 2025 | May 21, 2025 |
| DEFA14A | Additional proxy material | May 10, 2024 | — |
| DEF 14A | Proxy statement | May 10, 2024 | Jun 26, 2024 |
| DEFA14A | Additional proxy material | Apr 7, 2023 | — |
| DEF 14A | Proxy statement | Apr 7, 2023 | May 18, 2023 |
| DEFA14A | Additional proxy material | Sep 27, 2022 | — |
| DEFA14A | Additional proxy material | Sep 21, 2022 | — |
| DEF 14A | Proxy statement | Aug 25, 2022 | Oct 5, 2022 |
| PRE 14A | Preliminary proxy statement | Aug 15, 2022 | Oct 5, 2022 |
| DEFA14A | Additional proxy material | Apr 7, 2022 | — |
| DEF 14A | Proxy statement | Apr 7, 2022 | May 18, 2022 |
| DEFA14A | Additional proxy material | May 20, 2021 | — |
| DEFA14A | Additional proxy material | May 20, 2021 | — |
| DEF 14A | Proxy statement | Apr 19, 2021 | Apr 16, 2021 |
| DEFA14A | Additional proxy material | Apr 9, 2020 | — |
| DEFA14A | Additional proxy material | Mar 30, 2020 | — |
| DEF 14A | Proxy statement | Mar 4, 2020 | Mar 31, 2020 |
| PRE 14A | Preliminary proxy statement | Feb 21, 2020 | Feb 21, 2020 |
| DEF 14A | Proxy statement | Dec 23, 2019 | Jan 24, 2020 |
| PRE 14A | Preliminary proxy statement | Nov 4, 2019 | Dec 13, 2019 |
| DEFA14A | Additional proxy material | Feb 25, 2019 | — |
| DEF 14A | Proxy statement | Feb 25, 2019 | Feb 25, 2019 |
| PRE 14A | Preliminary proxy statement | Feb 14, 2019 | Apr 12, 2019 |
| DEFA14A | Additional proxy material | May 14, 2018 | — |
| DEF 14A | Proxy statement | May 9, 2018 | Jun 27, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 27, 2018 | Jun 27, 2018 |
| DEF 14A | Proxy statement | Jun 16, 2017 | Jul 26, 2017 |
| PRE 14A | Preliminary proxy statement | May 25, 2017 | May 25, 2017 |
| DEFA14A | Additional proxy material | Oct 5, 2016 | — |
| DEF 14A | Proxy statement | Oct 5, 2016 | Nov 15, 2016 |
| PRE 14A | Preliminary proxy statement | Sep 13, 2016 | Sep 13, 2016 |
| DEFA14A | Additional proxy material | Apr 21, 2016 | — |
| DEF 14A | Proxy statement | Apr 13, 2016 | May 24, 2016 |
| PRE 14A | Preliminary proxy statement | Mar 15, 2016 | Mar 15, 2016 |
| DEF 14C | Information statement | Jun 22, 2015 | Jun 22, 2015 |
| DEF 14A | Proxy statement | May 12, 2015 | Jun 1, 2015 |
| PRE 14A | Preliminary proxy statement | Apr 27, 2015 | May 4, 2015 |
| DEF 14C | Information statement | Feb 24, 2011 | Feb 22, 2011 |
| PRE 14C | Rosewind corp preliminary - notice of stockholder action | Feb 10, 2011 | Feb 9, 2011 |
| DEF 14C | Information statement | Jul 9, 2010 | Jul 12, 2010 |
| PRE 14C | Rosewind corp preliminary 14(c) information stmt | Jun 29, 2010 | Jun 29, 2010 |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AYTU (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Denver, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1385818
- Former names
- AYTU BIOSCIENCE, INC (until Mar 22, 2021); Rosewind CORP (until Jun 8, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.